Submucosal bioresorbable drug eluting platform
AssigneeIntersect ENT, Inc.
InventorsJohn Joseph STANKUS, James SU, Anthony J. ABBATE, Tu Duc NGO, Diego Javier GARNICA, Rahul Bitla
Life of this patent
Estimating the term…
Abstract
Systems and methods for delivering a therapeutic agent to target tissue using a plurality of drug delivery platforms each having the therapeutic drug embedded as part of the drug delivery platform. Each drug delivery platform is implanted into a target tissue, and the active agent elutes out of the drug delivery platform for a target period of time, delivering a therapeutic dose of the drug for that period of time. The duration of therapy for an implant can be from 3 to 12 months, longer, or shorter.
Claims21
(canceled)
A system for treating symptoms of a condition, comprising:
- a delivery device including a needle having a hollow interior and a distal tip configured for insertion through tissue to a target submucosal location;
- and
- a plurality of bioresorbable drug delivery platforms disposed within the hollow interior of the needle, each bioresorbable drug delivery platform of the plurality of bioresorbable drug platforms including a therapeutic agent having a biased distribution in a radial direction relative to a center of the bioresorbable drug delivery platform,
- wherein the delivery device is configured to deliver at least one bioresorbable drug delivery platform of the plurality of bioresorbable drug delivery platforms from the hollow interior of the needle, through the distal tip of the needle, to the target submucosal location for implantation therein and sustained release of the therapeutic agent at the target submucosal location over a period of time.
A system for treating symptoms of a condition, comprising:
- a delivery device including a needle having a hollow interior and a distal tip configured for insertion through tissue to a target submucosal location;
- and
- a plurality of bioresorbable drug delivery platforms disposed within the hollow interior of the needle, each bioresorbable drug delivery platform of the plurality of bioresorbable drug platforms including a therapeutic agent,
- wherein the delivery device is configured to deliver at least one bioresorbable drug delivery platform of the plurality of bioresorbable drug delivery platforms from the hollow interior of the needle, through the distal tip of the needle, to the target submucosal location for implantation therein and sustained release of the therapeutic agent at the target submucosal location over a period of time, and
- wherein the delivery device further includes at least one indicator configured to confirm delivery of the at least one bioresorbable drug delivery platform of the plurality of bioresorbable drug delivery platforms to the target submucosal location.
Dependencies are inferred from the claim text.